OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Drug Discovery is 79. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
AI serves up target and inhibitor for lung fibrosis	2231
Vaccine exposes tumours to immune cell attack	1309
Pfizer buys Biohaven’s migraine drugs for $11.6 billion	858
The importance of persistence in cancer drug development	738
A specific biomarker for insoluble tau	700
Targeting tumour-associated bacteria	574
A new path to targeted protein degradation?	550
Neutralizing Zika virus	544
The improving benefit–risk balance of phase I cancer trials	519
FDA approves a c-MET-targeted ADC for lung cancer	493
Tumour cells get a dendritic cell makeover	480
Glucose-sensitive insulin protects against hypoglycaemia	454
Promoting tissue repair after heart attack	434
mRNA-encoded monoclonal antibody fights CHIKV	414
Hypoimmune iPSCs escape immune detection	394
Lipid nanoparticle ferries therapeutic mRNA to the placenta	382
Targeting drug-resistant glioblastoma	347
Degrading cell-free DNA to prevent recurrent stroke	340
New antibiotic for urinary tract infections nabs FDA approval	314
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	304
Evolution of innovative drug R&D in China	300
Anti-tau antibody stumbles in phase II Alzheimer trial	300
FDA new drug approvals in Q1 2023	278
Targeting the Hippo pathway in cancer	277
Top companies and drugs by sales in 2021	276

Chemical engineering of CRISPR–Cas systems for therapeutic application	269
Apolipoprotein L2 inhibitor mitigates fibrosis	269
FDA approves second TTR stabilizer for cardiac amyloidosis	269
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	253
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval	253
2022 FDA approvals	239
Small-molecule discovery through DNA-encoded libraries	231
mRNA vaccines for infectious diseases — advances, challenges and opportunities	223
Increasing the potency of T cell therapies	223
Small molecule improves muscle function in myasthenia gravis	219
Blocking breast cancer metastasis	204
Reflections on 10 years of the FDA’s breakthrough therapy designation	203
FDA approves anti-CD3 antibody to delay type 1 diabetes onset	202
Pushing both sides of the drug pricing aisle	191
Host-directed antiviral blocks SARS-CoV-2 entry	188
TCR-engineered T cells get personal	179
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics	179
FDA new drug approvals in Q2 2023	178
The antibody–drug conjugate landscape	173
Base editors hit the clinic	166
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap	163
The significance of blockbusters in the pharmaceutical industry	163
Inhibiting ASGR1 boosts cholesterol removal	152
Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines	151
‘Bespoke Gene Therapy Consortium’ sets out to enable gene therapies for ultra-rare diseases	148
Amylin takes another shot at the obesity prize	145
Rewired proteostasis in KRAS inhibitor resistance	141
R&D re-balancing act	137
A call to action for translational sciences in COVID-19 and future pandemics	136
Mimicking the health benefits of exercise	135
Pan-coronavirus vaccine pipeline takes form	134
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer	134
Screening ultra-large virtual libraries	132
FDA approves second BCMA-targeted CAR-T cell therapy	119
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders	118
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape	112
The emerging role of mass spectrometry-based proteomics in drug discovery	110
Combating antimicrobial resistance in malaria, HIV and tuberculosis	108
Phenotypic drug discovery: recent successes, lessons learned and new directions	104
Antibody–drug conjugates come of age in oncology	102
Multi-TACs target solid tumours	99
FDA approves J&J’s FcRn blocker for generalized myasthenia gravis	98
The malignant melanoma market	97
Gut metabolite mediates nerve repair	96
Immunology on the brain	96
Reducing IL-2 toxicity	95
FDA approves first-in-class TRPM8 ion channel agonist for dry eye disease	90
Agonist antibody lowers blood pressure	90
LRRK2-targeted Parkinson disease drug advances into phase III	88
Monkeypox mRNA vaccine protects mice and macaques	87

Neglected tropical diseases go global	83
Anti-IL-11 antibody shows anti-ageing properties	83
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline	82
The European Innovation Network as a hub for medicines innovation in Europe	81